Studies
| Study First Submitted Date | 2020-09-23 |
| Study First Posted Date | 2020-10-08 |
| Last Update Posted Date | 2023-05-06 |
| Start Month Year | November 1, 2023 |
| Primary Completion Month Year | December 31, 2027 |
| Verification Month Year | May 2023 |
| Verification Date | 2023-05-31 |
| Last Update Posted Date | 2023-05-06 |
Detailed Descriptions
| Sequence: | 20718591 |
| Description | OUTLINE: This is a dose-escalation study of ²¹¹At-OKT10-B10. Patients are assigned to 1 of 2 arms. ARM A: Patients with HLA-matched related or unrelated donors receive ²¹¹At-OKT10-B10 intravenously (IV) on day -7 (day -10 to -5) and fludarabine IV over 30 minutes on days -4 to -2. Patients then undergo TBI and allogeneic HCT on day 0. ARM B: Patients with HLA-matched haploidentical donors receive ²¹¹At-OKT10-B10 IV on day -8 (day -14 to -7), fludarabine IV over 30 minutes on days -6 to -2, and cyclophosphamide IV over 1 hour on day -6 and -5. Patients then undergo TBI on day -1 and allogeneic HCT on day 0. |
Facilities
| Sequence: | 200073846 |
| Name | Fred Hutch/University of Washington Cancer Consortium |
| City | Seattle |
| State | Washington |
| Zip | 98109 |
| Country | United States |
Facility Contacts
| Sequence: | 28100329 |
| Facility Id | 200073846 |
| Contact Type | primary |
| Name | Damian Green |
| dgreen@fredhutch.org | |
| Phone | 206-667-5398 |
Facility Investigators
| Sequence: | 18327872 |
| Facility Id | 200073846 |
| Role | Principal Investigator |
| Name | Damian Green |
Browse Interventions
| Sequence: | 96037334 | Sequence: | 96037325 | Sequence: | 96037326 | Sequence: | 96037327 | Sequence: | 96037328 | Sequence: | 96037329 | Sequence: | 96037330 | Sequence: | 96037331 | Sequence: | 96037332 | Sequence: | 96037333 | Sequence: | 96037335 | Sequence: | 96037336 | Sequence: | 96037337 | Sequence: | 96037338 | Sequence: | 96037339 | Sequence: | 96037340 | Sequence: | 96037341 | Sequence: | 96037342 | Sequence: | 96037343 |
| Mesh Term | Immunologic Factors | Mesh Term | Cyclophosphamide | Mesh Term | Fludarabine | Mesh Term | Fludarabine phosphate | Mesh Term | Daratumumab | Mesh Term | Antineoplastic Agents, Immunological | Mesh Term | Antibodies | Mesh Term | Immunoglobulins | Mesh Term | Antibodies, Monoclonal | Mesh Term | Immunosuppressive Agents | Mesh Term | Physiological Effects of Drugs | Mesh Term | Antirheumatic Agents | Mesh Term | Antineoplastic Agents, Alkylating | Mesh Term | Alkylating Agents | Mesh Term | Molecular Mechanisms of Pharmacological Action | Mesh Term | Antineoplastic Agents | Mesh Term | Myeloablative Agonists | Mesh Term | Antimetabolites, Antineoplastic | Mesh Term | Antimetabolites |
| Downcase Mesh Term | immunologic factors | Downcase Mesh Term | cyclophosphamide | Downcase Mesh Term | fludarabine | Downcase Mesh Term | fludarabine phosphate | Downcase Mesh Term | daratumumab | Downcase Mesh Term | antineoplastic agents, immunological | Downcase Mesh Term | antibodies | Downcase Mesh Term | immunoglobulins | Downcase Mesh Term | antibodies, monoclonal | Downcase Mesh Term | immunosuppressive agents | Downcase Mesh Term | physiological effects of drugs | Downcase Mesh Term | antirheumatic agents | Downcase Mesh Term | antineoplastic agents, alkylating | Downcase Mesh Term | alkylating agents | Downcase Mesh Term | molecular mechanisms of pharmacological action | Downcase Mesh Term | antineoplastic agents | Downcase Mesh Term | myeloablative agonists | Downcase Mesh Term | antimetabolites, antineoplastic | Downcase Mesh Term | antimetabolites |
| Mesh Type | mesh-ancestor | Mesh Type | mesh-list | Mesh Type | mesh-list | Mesh Type | mesh-list | Mesh Type | mesh-list | Mesh Type | mesh-list | Mesh Type | mesh-list | Mesh Type | mesh-list | Mesh Type | mesh-list | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor |
Conditions
| Sequence: | 52162495 | Sequence: | 52162496 | Sequence: | 52162497 |
| Name | Plasma Cell Myeloma | Name | Recurrent Plasma Cell Myeloma | Name | Refractory Plasma Cell Myeloma |
| Downcase Name | plasma cell myeloma | Downcase Name | recurrent plasma cell myeloma | Downcase Name | refractory plasma cell myeloma |
Id Information
| Sequence: | 40152582 | Sequence: | 40152583 | Sequence: | 40152584 | Sequence: | 40152585 |
| Id Source | org_study_id | Id Source | secondary_id | Id Source | secondary_id | Id Source | secondary_id |
| Id Value | RG1121028 | Id Value | NCI-2020-06835 | Id Value | 10467 | Id Value | P01CA078902 |
| Id Type | Registry Identifier | Id Type | Other Identifier | Id Type | U.S. NIH Grant/Contract | ||
| Id Type Description | CTRP (Clinical Trial Reporting Program) | Id Type Description | Fred Hutch/University of Washington Cancer Consortium | ||||
| Id Link | https://reporter.nih.gov/quickSearch/P01CA078902 |
Countries
| Sequence: | 42561999 |
| Name | United States |
| Removed | False |
Design Groups
| Sequence: | 55584610 | Sequence: | 55584611 |
| Group Type | Experimental | Group Type | Experimental |
| Title | Arm A (²¹¹At-OKT10-B10, fludarabine, TBI, HCT) | Title | Arm B (²¹¹At-OKT10-B10, chemotherapy, TBI, HCT) |
| Description | Patients with HLA-matched related or unrelated donors receive ²¹¹At-OKT10-B10 IV on day -7 (day -10 to -5) and fludarabine IV over 30 minutes on days -4 to -2. Patients then undergo TBI and allogeneic HCT on day 0. | Description | Patients with HLA-matched haploidentical donors receive ²¹¹At-OKT10-B10 IV on day -8 (day -14 to -7), fludarabine IV over 30 minutes on days -6 to -2, and cyclophosphamide IV over 1 hour on day -6 and -5. Patients then undergo TBI on day -1 and allogeneic HCT on day 0. |
Interventions
| Sequence: | 52477762 | Sequence: | 52477758 | Sequence: | 52477759 | Sequence: | 52477760 | Sequence: | 52477761 |
| Intervention Type | Radiation | Intervention Type | Procedure | Intervention Type | Biological | Intervention Type | Drug | Intervention Type | Drug |
| Name | Total-Body Irradiation | Name | Allogeneic Hematopoietic Stem Cell Transplantation | Name | Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10 | Name | Cyclophosphamide | Name | Fludarabine Phosphate |
| Description | Undergo TBI | Description | Undergo HCT | Description | Given IV | Description | Given IV | Description | Given IV |
Design Outcomes
| Sequence: | 177349466 | Sequence: | 177349465 | Sequence: | 177349467 | Sequence: | 177349468 | Sequence: | 177349469 | Sequence: | 177349470 |
| Outcome Type | secondary | Outcome Type | primary | Outcome Type | secondary | Outcome Type | secondary | Outcome Type | secondary | Outcome Type | secondary |
| Measure | Disease response | Measure | Maximum tolerated dose (MTD) of radiation delivered via ²¹¹At-OKT10-B10 | Measure | Duration of response | Measure | Minimal residual disease (MRD) | Measure | One-year disease -free survival | Measure | One-year overall survival (OS) |
| Time Frame | Between days 70 to 90 post-transplant | Time Frame | Up to 100 days following HCT | Time Frame | From date of response assessment (days +70-90 following allogeneic HCT) until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years | Time Frame | Between days 70 to 90 post-transplant | Time Frame | From allogeneic hematopoietic cell transplantation to disease progression, relapse or death, assessed at 1 year | Time Frame | From transplantation to death or last patient contact, assessed at 1 year |
| Description | Definition of disease status will be performed using the established International Myeloma Working Group (IMWG) response criteria for stringent complete response, complete response, partial response (PR) and no response. Relapse is defined per IMWG criteria. The response rates (PR or better) will be estimated along with the exact 95% confidence interval. | Description | MTD is defined as the dose of ²¹¹At-OKT10-B10 associated with a true dose limiting toxicity (DLT) rate of 25%, where DLT is defined as grade III/IV regimen-related toxicity according to the Bearman Scale. | Description | Duration of response will be estimated using Kaplan-Meier methodology. | Description | MRD will be assessed in the comprehensive response evaluation/restaging. The proportion who achieve MRD will be estimated along with an exact 95% confidence interval. | Description | Kaplan-Meier methodology will be used to estimate the 1-year disease-free survival. | Description | Kaplan-Meier methodology will be used to estimate the 1-year OS. |
Browse Conditions
| Sequence: | 193455179 | Sequence: | 193455170 | Sequence: | 193455171 | Sequence: | 193455172 | Sequence: | 193455173 | Sequence: | 193455174 | Sequence: | 193455175 | Sequence: | 193455176 | Sequence: | 193455177 | Sequence: | 193455178 | Sequence: | 193455180 | Sequence: | 193455181 | Sequence: | 193455182 | Sequence: | 193455183 |
| Mesh Term | Hematologic Diseases | Mesh Term | Multiple Myeloma | Mesh Term | Neoplasms, Plasma Cell | Mesh Term | Neoplasms by Histologic Type | Mesh Term | Neoplasms | Mesh Term | Hemostatic Disorders | Mesh Term | Vascular Diseases | Mesh Term | Cardiovascular Diseases | Mesh Term | Paraproteinemias | Mesh Term | Blood Protein Disorders | Mesh Term | Hemorrhagic Disorders | Mesh Term | Lymphoproliferative Disorders | Mesh Term | Immunoproliferative Disorders | Mesh Term | Immune System Diseases |
| Downcase Mesh Term | hematologic diseases | Downcase Mesh Term | multiple myeloma | Downcase Mesh Term | neoplasms, plasma cell | Downcase Mesh Term | neoplasms by histologic type | Downcase Mesh Term | neoplasms | Downcase Mesh Term | hemostatic disorders | Downcase Mesh Term | vascular diseases | Downcase Mesh Term | cardiovascular diseases | Downcase Mesh Term | paraproteinemias | Downcase Mesh Term | blood protein disorders | Downcase Mesh Term | hemorrhagic disorders | Downcase Mesh Term | lymphoproliferative disorders | Downcase Mesh Term | immunoproliferative disorders | Downcase Mesh Term | immune system diseases |
| Mesh Type | mesh-ancestor | Mesh Type | mesh-list | Mesh Type | mesh-list | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor |
Sponsors
| Sequence: | 48311667 | Sequence: | 48311668 |
| Agency Class | OTHER | Agency Class | NIH |
| Lead Or Collaborator | lead | Lead Or Collaborator | collaborator |
| Name | Fred Hutchinson Cancer Center | Name | National Cancer Institute (NCI) |
Overall Officials
| Sequence: | 29281131 |
| Role | Principal Investigator |
| Name | Damian Green |
| Affiliation | Fred Hutch/University of Washington Cancer Consortium |
Central Contacts
| Sequence: | 12006463 |
| Contact Type | primary |
| Name | Damian Green |
| Phone | 206.667.5398 |
| dgreen@fredhutch.org | |
| Role | Contact |
Design Group Interventions
| Sequence: | 68138713 | Sequence: | 68138714 | Sequence: | 68138715 | Sequence: | 68138716 | Sequence: | 68138717 | Sequence: | 68138718 | Sequence: | 68138719 | Sequence: | 68138720 | Sequence: | 68138721 |
| Design Group Id | 55584610 | Design Group Id | 55584611 | Design Group Id | 55584610 | Design Group Id | 55584611 | Design Group Id | 55584611 | Design Group Id | 55584610 | Design Group Id | 55584611 | Design Group Id | 55584610 | Design Group Id | 55584611 |
| Intervention Id | 52477758 | Intervention Id | 52477758 | Intervention Id | 52477759 | Intervention Id | 52477759 | Intervention Id | 52477760 | Intervention Id | 52477761 | Intervention Id | 52477761 | Intervention Id | 52477762 | Intervention Id | 52477762 |
Eligibilities
| Sequence: | 30760826 |
| Gender | All |
| Minimum Age | 18 Years |
| Maximum Age | 70 Years |
| Healthy Volunteers | No |
| Criteria | Inclusion Criteria: Patients with newly diagnosed or relapsed/refractory multiple myeloma Patients with multiple myeloma must have at least one of the following high-risk features: t(4;14), t(14;16), t(14;20) or deletion 17p, gain in chromosome 1q (> 3 copies of CKS1b) by fluorescence in situ hybridization (FISH); hypodiploidy; complex karyotype Revised International Staging System III Plasmablastic morphology History of primary or secondary plasma cell leukemia Patients must start ²¹¹At-OKT10-B10 within 40-180 days of autologous stem cell transplant (either as part of their induction, or as salvage) Patients must have an estimated creatinine clearance greater than 50/ml per minute measured by 24-hour urine collection Total bilirubin < 2 times the upper limit of normal Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 times the upper limit of normal) Patients must have an Eastern Cooperative Oncology Group (ECOG) =< 2 or Karnofsky >= 70 Patients must have CD38+ myeloma cells as demonstrated by either flow cytometry or immunohistochemistry in most recent bone marrow that had evidence of clonal plasma cells For patients of childbearing potential, must have a negative urinary pregnancy test on the day of and prior to infusion of ²¹¹At-OKT10-B10 Ability to provide informed consent Patients must have an HLA-matched related donor or an HLA-matched unrelated donor who meets standard Seattle Cancer Care Alliance (SCCA) and/or National Marrow Donor Program (NMDP) or other donor center criteria for peripheral blood stem cell (PBSC) or bone marrow donation, as follows: Related donor: related to the patient and genotypically or phenotypically identical for HLA-A, B, C, DRB1 and DQB1. Phenotypic identity must be confirmed by high-resolution typing Unrelated donor: Matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing; OR Mismatched for a single allele without antigen mismatching at HLA-A, B, or C as defined by high resolution typing but otherwise matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing Donors are excluded when preexisting immunoreactivity is identified that would jeopardize donor hematopoietic cell engraftment. The recommended procedure for patients with 10 of 10 HLA allele level (phenotypic) match is to obtain panel reactive antibody (PRA) screens to class I and class II antigens for all patients before HCT. If the PRA shows > 10% activity, then flow cytometric or B and T cell cytotoxic cross matches should be obtained. The donor should be excluded if any of the cytotoxic cross match assays are positive. For those patients with an HLA class I allele mismatch, flow cytometric or B and T cell cytotoxic cross matches should be obtained regardless of the PRA results. A positive anti-donor cytotoxic crossmatch is an absolute donor exclusion Patient and donor pairs homozygous at a mismatched allele in the graft rejection vector are considered a two-allele mismatch, i.e., the patient is A*0101 and the donor is A*0102, and this type of mismatch is not allowed Patients without an HLA-matched related or unrelated donor available must have a related donor who is identical for one HLA haplotype and mismatched at the HLA-A, -B or DRB1 loci of the unshared haplotype with the exception of single HLA-A, -B or DRB1 mismatches Exclusion Criteria: History of central nervous system involvement by multiple myeloma Presence of circulating plasma cells in the peripheral blood of 5% or more by flow cytometry or morphology Prior radioimmunotherapy or radiation of > 20 Gy to pelvis or at maximally tolerated levels to any critical normal organ Prior allogeneic HCT More than two prior autologous HCTs Patients with plasmacytomas > 1 cm in bone marrow or any extramedullary plasmacytoma. Previously fludeoxyglucose F-18 (FDG) avid mass lesions by positron emission tomography (PET) that are no longer hypermetabolic following the most recent cycle of therapy are exempt, as are plasmacytomas irradiated with curative intent (>= 35 Gy) Patients with symptomatic coronary artery disease defined as having angina or anginal equivalent, and/or arrhythmias requiring anti-arrhythmics for rhythm control History of reactive airway disease and clinically significant asthma requiring ongoing treatment Patients with the following organ dysfunction: Left ventricular ejection fraction < 40% in patients with HLA-matched or unrelated donor or < 45% in patients with an HLA-haploidentical donor New York Heart Association (NYHA) class > 1 heart failure Corrected diffusing capacity of the lungs for carbon monoxide (DLCO) < 50% or receiving supplemental continuous oxygen. When pulmonary function tests cannot be obtained, the 6-minute walk test (6MWT, also known as exercise oximetry) will be used: Any patient with oxygen saturation on room air of < 90% during a 6MWT will be excluded Liver abnormalities: fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction as evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis, or symptomatic biliary disease Patients who are known to be seropositive for human immunodeficiency virus (HIV) Perceived inability to tolerate diagnostic or therapeutic procedures Women of childbearing potential who are pregnant (beta-human chorionic gonadotropin [HCG]+) or breast feeding Fertile men and women unwilling to use contraceptives during and for 12 months post-transplant Uncontrolled or untreated active infection Patients with known AL subtype amyloidosis Inability to understand or give an informed consent Known allergy to murine-based monoclonal antibodies Known contraindications to radiotherapy History of another primary malignancy that has not been in remission for at least 2 years. The following are exempt from the 2-year-limit: nonmelanoma skin cancer, curatively treated localized prostate cancer, or cervical carcinoma in situ or squamous intraepithelial lesion on papanicolaou (PAP) smear Therapy with anti-CD38 monoclonal antibody within 3 months of ²¹¹At-OKT10-B10 infusion Prior therapy with radiolabeled monoclonal antibodies Any history of treatment with checkpoint inhibitor/s |
| Adult | True |
| Child | False |
| Older Adult | True |
Calculated Values
| Sequence: | 254304485 |
| Number Of Facilities | 1 |
| Registered In Calendar Year | 2020 |
| Were Results Reported | False |
| Has Us Facility | True |
| Has Single Facility | True |
| Minimum Age Num | 18 |
| Maximum Age Num | 70 |
| Minimum Age Unit | Years |
| Maximum Age Unit | Years |
| Number Of Primary Outcomes To Measure | 1 |
| Number Of Secondary Outcomes To Measure | 5 |
Designs
| Sequence: | 30507028 |
| Allocation | Non-Randomized |
| Intervention Model | Parallel Assignment |
| Observational Model | |
| Primary Purpose | Treatment |
| Time Perspective | |
| Masking | None (Open Label) |
Intervention Other Names
| Sequence: | 26668768 | Sequence: | 26668769 | Sequence: | 26668770 | Sequence: | 26668771 | Sequence: | 26668772 | Sequence: | 26668773 | Sequence: | 26668774 | Sequence: | 26668775 | Sequence: | 26668776 | Sequence: | 26668777 | Sequence: | 26668778 | Sequence: | 26668779 | Sequence: | 26668780 | Sequence: | 26668781 | Sequence: | 26668782 | Sequence: | 26668783 | Sequence: | 26668784 | Sequence: | 26668785 | Sequence: | 26668786 | Sequence: | 26668787 | Sequence: | 26668788 | Sequence: | 26668789 | Sequence: | 26668790 | Sequence: | 26668791 | Sequence: | 26668792 | Sequence: | 26668793 | Sequence: | 26668794 | Sequence: | 26668795 | Sequence: | 26668796 | Sequence: | 26668797 | Sequence: | 26668798 | Sequence: | 26668799 | Sequence: | 26668800 | Sequence: | 26668801 | Sequence: | 26668802 | Sequence: | 26668803 | Sequence: | 26668804 | Sequence: | 26668805 | Sequence: | 26668806 | Sequence: | 26668807 | Sequence: | 26668808 | Sequence: | 26668809 | Sequence: | 26668810 | Sequence: | 26668811 | Sequence: | 26668812 | Sequence: | 26668813 | Sequence: | 26668814 | Sequence: | 26668815 | Sequence: | 26668816 | Sequence: | 26668817 | Sequence: | 26668818 | Sequence: | 26668819 | Sequence: | 26668820 | Sequence: | 26668821 | Sequence: | 26668822 | Sequence: | 26668823 |
| Intervention Id | 52477758 | Intervention Id | 52477758 | Intervention Id | 52477758 | Intervention Id | 52477758 | Intervention Id | 52477758 | Intervention Id | 52477758 | Intervention Id | 52477759 | Intervention Id | 52477759 | Intervention Id | 52477759 | Intervention Id | 52477759 | Intervention Id | 52477759 | Intervention Id | 52477759 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477760 | Intervention Id | 52477761 | Intervention Id | 52477761 | Intervention Id | 52477761 | Intervention Id | 52477761 | Intervention Id | 52477761 | Intervention Id | 52477762 | Intervention Id | 52477762 | Intervention Id | 52477762 | Intervention Id | 52477762 | Intervention Id | 52477762 |
| Name | Allogeneic | Name | Allogeneic Hematopoietic Cell Transplantation | Name | Allogeneic Stem Cell Transplantation | Name | HSC | Name | HSCT | Name | Stem Cell Transplantation, Allogeneic | Name | ²¹¹At-OKT10-B10 | Name | [²¹¹At]OKT10-B10 | Name | Astatine 211-labeled Anti-CD38 Monoclonal Antibody OKT10-B10 | Name | Astatine At 211 Anti-CD38 MoAb OKT10-B10 | Name | Astatine-211-OKT10-B10 | Name | At211-OKT10-B10 | Name | (-)-Cyclophosphamide | Name | 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate | Name | Carloxan | Name | Ciclofosfamida | Name | Ciclofosfamide | Name | Cicloxal | Name | Clafen | Name | Claphene | Name | CP monohydrate | Name | CTX | Name | CYCLO-cell | Name | Cycloblastin | Name | Cycloblastine | Name | Cyclophospham | Name | Cyclophosphamid monohydrate | Name | Cyclophosphamide Monohydrate | Name | Cyclophosphamidum | Name | Cyclophosphan | Name | Cyclophosphane | Name | Cyclophosphanum | Name | Cyclostin | Name | Cyclostine | Name | Cytophosphan | Name | Cytophosphane | Name | Cytoxan | Name | Fosfaseron | Name | Genoxal | Name | Genuxal | Name | Ledoxina | Name | Mitoxan | Name | Neosar | Name | Revimmune | Name | Syklofosfamid | Name | WR- 138719 | Name | 2-F-ara-AMP | Name | 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)- | Name | Beneflur | Name | Fludara | Name | SH T 586 | Name | SCT_TBI | Name | TBI | Name | Total Body Irradiation | Name | Whole Body Irradiation | Name | Whole-Body Irradiation |
Responsible Parties
| Sequence: | 28873307 |
| Responsible Party Type | Sponsor |